The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.
 
Lakshmi Nayak
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
John L. Hays
Consulting or Advisory Role - Eisai
 
Alona Muzikansky
No Relationships to Disclose
 
Sarah C. Gaffey
No Relationships to Disclose
 
Khanh Tu Do
No Relationships to Disclose
 
Vinay K. Puduvalli
Honoraria - DePuy Companies; Foundation Medicine; Nektar; Orbus Therapeutics
Consulting or Advisory Role - Foundation Medicine; Genentech; Nektar; Threshold Pharmaceuticals
Research Funding - DNAtrix; Genentech; Plexxikon
 
Eudocia Quant Lee
Consulting or Advisory Role - Genentech
 
Mikael L. Rinne
No Relationships to Disclose
 
Andrew David Norden
Consulting or Advisory Role - Celldex; VBL Therapeutics
 
Rameen Beroukhim
Consulting or Advisory Role - Gilead Sciences (I); Novartis
Research Funding - Novartis
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; Angiochem; AstraZeneca; Cavion; Celldex; Exelixis; Genentech/Roche; GlaxoSmithKline; Karyopharm Therapeutics; Midatech Pharma; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Sanofi; Sigma-Tau; Vascular Biogenics
Speakers' Bureau - Merck
 
L. Austin Doyle
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; EMD Serono; G1 Therapeutics; Lilly; Takeda; Tesaro; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
David A. Reardon
Honoraria - Abbvie; Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oxigene; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oxigene; Regeneron; Stemline Therapeutics
Research Funding - Celldex (Inst); Incyte (Inst); Midatech Pharma (Inst)